Selegiline is the only FDA-approved drug for canine cognitive dysfunction syndrome (CCDS) and is the most commonly recommended pharmacologic treatment, dosed at 0.5–1 mg/kg PO once daily in the morning for 30 days, with dose adjustment to the next tablet size if no improvement is seen at the lower dose.AAHA Clinical G… Selegiline is effective in up to 70% of dogs with CCDS.AAHA Clinical G… Toxicity occurs when selegiline is combined with other antidepressants, narcotics, phenylpropanolamine, or other monoamine oxidase inhibitors — these combinations are contraindicated.AAHA Clinical G…
Despite selegiline's approval status, only approximately 30% of veterinarians consider it the most effective option, reflecting genuine clinical uncertainty about treatment efficacy across the board.Frontiers in Ve… No other pharmacologic agent currently carries a label indication for CCDS in the United States.AAHA Clinical G…+1
For anxiety associated with CCDS, shorter-acting anxiolytics are preferred over benzodiazepines with long half-lives. Trazodone and alprazolam are preferred by the 2023 AAHA Senior Care task force for their rapid onset, rapid clearance, and limited side-effect profile.AAHA Clinical G… Diazepam is specifically avoided because it has been reported to exacerbate dementia signs.AAHA Clinical G… Clomipramine carries an FDA label for canine separation anxiety but not for CCDS-associated anxiety, and fluoxetine carries a label for canine separation anxiety only — both are used off-label in this context.AAHA Clinical G…+1 Fluoxetine, when used, is dosed at 0.7 mg/kg PO q24h in reported cases, with full effects expected at 4–6 weeks.Journal of the… Gabapentin has been described as an adjunctive treatment for CCDS-associated anxiety at 14.3 mg/kg PO q12h in reported cases, with adverse effects including sedation, ataxia, lethargy, and vomiting.Journal of the…
Onset of therapeutic effect for daily medications such as selective serotonin reuptake inhibitors and tricyclic antidepressants may not appear for 5–8 weeks due to the time required for regional brain receptor changes.AAHA Clinical G…
Environmental management and nutritional intervention are recommended as complements to pharmacologic treatment, with the greatest benefit when initiated early in disease progression.Veterinary Clin…+1 Diets high in antioxidants and medium-chain triglycerides show the most positive effect when combined with environmental enrichment — specifically exercise, new toys, cognitive games, tasks, and agility training.AAHA Clinical G… Omega-3 fatty acids and vitamins are additional dietary modifications with reported impact on brain function in aged dogs.Journal of the…
Severity staging using a validated behavioral questionnaire should guide treatment intensity and monitor response. The Canine Dementia Scale (CADES) is predictive of cognitive impairment progression, and serial scores documented in the medical record serve as both a treatment monitoring tool and a client education resource.AAHA Clinical G…+1 The 2025 CCDS Working Group defines three severity stages — mild (subtle, low-frequency signs with preserved function), moderate (apparent behavioral changes requiring management adjustments), and severe (debilitating deficits impairing basic function requiring comprehensive support) — using the DISHAA behavioral domains: disorientation, social interaction, sleep disruption, house soiling, learning and memory, activity changes, and anxiety.Journal of the…
| Drug | Dose / Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| Selegiline | 0.5–1 mg/kg PO q24h (morning); reassess at 30 days | Effective in up to 70% of dogs | Contraindicated with antidepressants, narcotics, phenylpropanolamine, MAOIs AAHA Clinical G… |
| Trazodone | Preferred short-acting anxiolytic; specific dose not established in sources | Rapid onset; limited side-effect profile | Not labeled for CCDS; off-label use AAHA Clinical G… |
| Alprazolam | Preferred short-acting anxiolytic; specific dose not established in sources | Rapid onset and clearance | Not labeled for CCDS; off-label use AAHA Clinical G… |
| Fluoxetine | 0.7 mg/kg PO q24h (reported case) | Full effect at 4–6 weeks | Labeled for separation anxiety only; adverse effects include reduced appetite, sedation, vomiting, diarrhea, anxiety, tremors AAHA Clinical G…+1 |
| Gabapentin | 14.3 mg/kg PO q12h (reported case) | Adjunctive for anxiety | Adverse effects: sedation, ataxia, lethargy, vomiting Journal of the… |
| Antioxidant/MCT diet + enrichment | Combined dietary and environmental protocol | Most positive effect when combined | Quality and rigor of supplement/nutraceutical research is limited AAHA Clinical G… |
Would you like guidance on how to stage CCDS severity using the DISHAA framework and select the appropriate treatment intensity for each stage?